News Shire plans filing for HAE drug after phase 3 success Lanadelumab could revolutionise treatment of swelling disease.
News CEO Meek looks to boost Ipsen with drug acquisitions Could French biotech snap up remaining rights to pancreatic cancer drug?
News Novartis takes option on NASH drug from Conatus Swiss pharma takes option on FXR agonist emricasan.
News PatientsLikeMe and Shire to co-develop rare disease patient ... Data from the new platform will help inform rare disease drug development.
News Novartis takes aim at Shire and Allergan with dry-eye drug Swiss company takes option on Lubris' ECF843.
News Alexion appoints former Baxalta chief Hantson as CEO Former AZ chief David Brennan expected to take over as chairman in May.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
